首页> 美国卫生研究院文献>Scientific Reports >Resensitization of Akt Induced Docetaxel Resistance in Breast Cancer by ‘Iturin A’ a Lipopeptide Molecule from Marine Bacteria Bacillus megaterium
【2h】

Resensitization of Akt Induced Docetaxel Resistance in Breast Cancer by ‘Iturin A’ a Lipopeptide Molecule from Marine Bacteria Bacillus megaterium

机译:海洋细菌杆菌的脂肽分子 Iturin A对乳腺癌引起的Akt诱导的多西他赛耐药性的重新敏化

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Development of the resistance is the major problem in cancer therapy. Docetaxel is a taxol alkaloid that is frequently used in metastatic breast cancer. However, resistance often limits the usefulness of this drug in many breast cancer patients. Manipulation of resistant cells to re-sensitize to the therapeutic effect of docetaxel is current strategy to overcome this problem. Here, we have introduced ‘Iturin A’ as a potent chemosensitizer in docetaxel resistant breast cancer cells. Combination of Iturin A and docetaxel treatment significantly hampered the proliferation of docetaxel resistant MDA-MB-231 and MDA-MB-468 breast cancer cells. Cell cycle analysis also showed massive amount of apoptotic population (Sub G0/G1) in combination therapy. A number of apoptotic and anti-apoptotic proteins were significantly altered in dual drug treated groups. Caspase 3 dependent cell death was observed in dual treatment. Molecular mechanism study showed that over-expression of Akt and its downstream signaling pathway was associated with docetaxel resistance. Iturin A significantly reduced Akt signaling pathway in resistant cells. This mechanistic action might be the reason behind the chemo-sensitization effect of Iturin A in docetaxel resistant breast cancer cells. In conclusion, Iturin A resensitized the resistant breast cancer cells to docetaxel therapy by inhibiting Akt activity.
机译:抗药性的发展是癌症治疗中的主要问题。多西紫杉醇是紫杉醇生物碱,常用于转移性乳腺癌。但是,耐药性常常限制了该药物在许多乳腺癌患者中的用途。操纵抗性细胞以使其对多西他赛的治疗作用重新敏感是克服该问题的当前策略。在这里,我们引入了“ Iturin A”作为对多西他赛耐药的乳腺癌细胞的有效化学增敏剂。 Iturin A和多西他赛的组合治疗显着阻碍了多西他赛耐药的MDA-MB-231和MDA-MB-468乳腺癌细胞的增殖。细胞周期分析还显示在联合治疗中大量凋亡细胞群(Sub G0 / G1)。在双重药物治疗组中,许多凋亡和抗凋亡蛋白发生了显着改变。在双重治疗中观察到胱天蛋白酶3依赖性细胞死亡。分子机制研究表明,Akt及其下游信号通路的过度表达与多西他赛耐药有关。 Iturin A显着降低了抗性细胞中的Akt信号通路。这种机制作用可能是Iturin A对多西他赛耐药的乳腺癌细胞产生化学致敏作用背后的原因。总之,伊图灵A通过抑制Akt活性使耐药乳腺癌细胞对多西他赛疗法重新敏感。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号